Eyal Shemesh still remembers the moment he realized a simple blood test could save a teenager’s transplanted liver. At Mount Sinai Kravis Children's Hospital in New York, the pediatrician and psychiatrist had long watched adolescents struggle with the relentless routine of post-transplant care—until a new tool, built from data already hiding in electronic health records, began revealing who was silently falling behind. The medication level variability index (MLVI), developed by Shemesh and his team at the Icahn School of Medicine at Mount Sinai, is now proving to be a quiet revolution in transplant medicine. Across 13 pediatric transplant centers in the U.S. and Canada, researchers used MLVI to screen over 3,000 liver transplant patients, zeroing in on 148 adolescents and young adults flagged as high risk due to erratic immunosuppressant levels. These fluctuations, long dismissed as noise, turned out to be a powerful signal: patients weren’t taking their medications consistently, putting them on a path toward rejection.
Medication nonadherence has long been a silent crisis in transplant care, especially among young people navigating independence, school, and social pressures. Unlike self-reports or costly monitoring, MLVI uses routine lab results—data collected during standard check-ups—to objectively identify risk. When patients in the study were assigned to a two-year remote behavioral intervention, the results were striking: those receiving support from trained specialists via telehealth experienced about half as many rejection-related events and retransplants as those on standard care. Even more telling, the mere use of MLVI across study sites seemed to shift outcomes—overall rejection rates dropped to levels typically seen in low-risk patients, suggesting that early detection alone can drive better care.
The implications extend beyond liver transplants. As Dr. Benjamin L. Shneider of Texas Children’s and Baylor College of Medicine points out, the challenge of sticking to complex medical regimens touches every corner of chronic disease management. What makes this study remarkable is not just its clinical impact, but its resilience: the telehealth intervention maintained engagement throughout the disruptions of the COVID-19 pandemic, enrolling and retaining patients when in-person care faltered. Though the trial didn’t reach statistical significance on its primary endpoint—largely because rejection rates were lower than expected in both groups—the real-world effect is undeniable. Clinicians now have a scalable, data-driven way to target support where it’s needed most.
As MLVI begins to spread beyond research centers, it carries the promise of turning routine data into life-saving insight. For young transplant patients, that could mean fewer hospital stays, stronger long-term outcomes, and the chance to live fully—without the shadow of rejection looming overhead.